Functional imaging as a tool to investigate the relationship between genetic variation and response to treatment with antipsychotics

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2560-2572

  Di Giorgio, A ^a   Sambataro, F ^a,b   Bertolino, A ^a,c  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c IRCCSS Casa Sollievo della Sofferenza ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; GENE PRODUCT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHOPROTEIN; PROTEIN DAT1; PROTEIN KINASE B; PROTEIN PPP1R1B; PROTEIN SLC6A3; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALLELE; AMYGDALOID NUCLEUS; BRAIN BLOOD FLOW; BRAIN METABOLISM; CAUCASIAN; CINGULATE GYRUS; COGNITION; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; DRUG RESPONSE; EPISODIC MEMORY; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE ACTIVITY; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCOSE METABOLISM; HAPLOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; LONG TERM CARE; METABOLIC RATE; MOTOR ACTIVITY; NEGATIVE SYNDROME; NEUROIMAGING; NUCLEIC ACID BASE SUBSTITUTION; OCCIPITAL LOBE; PHARMACOGENETICS; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOPHARMACOLOGY; RACE DIFFERENCE; RADIOACTIVITY; REVIEW; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SENSORIMOTOR FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL LOBE; VARIABLE NUMBER OF TANDEM REPEAT;

ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 69249144105     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957483     Document Type: Review

References (166)

1. Malhotra AK, Murphy GM, Jr., Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-96.
2. DeLisi LE, Dauphinais D. Neuroleptic responsiveness in siblings concordant for schizophrenia. Arch Gen Psychiatry 1989; 46: 477.
3. Horacek J, Libiger J, Hoschl C, Borzova K, Hendrychova I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 2001; 5: 71-3.
4. Mata I, Madoz V, Arranz MJ, Sham P, Murray RM. Olanzapine: Concordant response in monozygotic twins with schizophrenia. Br J Psychiatry 2001; 178: 86.
5. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-9.
6. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, et al. Clozapine-induced weight gain: A study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005; 15: 285-9.
7. Vojvoda D, Grimmell K, Sernyak M, Mazure CM. Monozygotic twins concordant for response to clozapine. Lancet 1996; 347: 61.
8. Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988; 153: 376-81.
9. Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM. Clozapine: Weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005; 133: 273-6.
10. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol Psychiatry 2007; 12: 707-47.
11. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: The path to discovery. Dialogues Clin Neurosci 2006; 8: 137-42.
12. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 1993; 91: 111-34.
13. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-9.
14. Carlsson A. The dopamine theory revisited. In: Hirsch S, Weinberger D, Eds, Schizophrenia. Oxford: Blackwell Science 1995; pp. 379-400.
15. Grandy DK, Zhou QY, Allen L, Litt R, Magenis RE, Civelli O, et al. A human D1 dopamine receptor gene is located on chromosome 5 at q35.1 and identifies an EcoRI RFLP. Am J Hum Genet 1990; 47: 828-34.
16. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203.
17. Dahmen N, Muller MJ, Germeyer S, Rujescu D, Anghelescu I, Hiemke C, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophr Res 2001; 49: 223-5.
18. Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 2002; 56: 97-102.
19. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001; 158: 802-4.
20. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545-50.
21. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005; 376: 1-4.
22. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005; 181: 179-87.
23. Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006; 16: 248-59.
24. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004; 7: 461-70.
25. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163: 529-31.
26. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: Are we ready for widespread clinical use? Schizophr Bull 2008; 34: 1130-44.
27. Noble E. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 2003; 116: 103-25.
28. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-6.
29. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-5.
30. Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2008.
31. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10: 335-41.
32. Mata I, Arranz MJ, Mancama D. The serotoninergic system influences individual's response to risperidone. Am J Med Genet 2002; 114: 728.
33. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998; 8: 481-4.
34. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-82.
35. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3: 356-61.
36. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104: 20552-7.
37. Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 2008.
38. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995; 16: 270-5.
39. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson EG, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992; 2: 249-54.
40. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068-72.
41. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992; 29: 858-60.
42. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25: 6-11.
43. Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients.. Eur Neuropsychopharmacol 1999; 10: 17-20.
44. Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 1-5.
45. Adams DH, Close S, Farmen M, Downing AM, Breier A, Houston JP. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008; 23: 267-74.
46. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15: 143-51.
47. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002; 162: 18-23.
48. Petronis A, Van Tol HH, Lichter JB, Livak KJ, Kennedy JL. The D4 dopamine receptor gene maps on 11p proximal to HRAS. Genomics 1993; 18: 161-3.
49. Barr CL, Kennedy JL, Lichter JB, Van Tol HH, Wetterberg L, Livak KJ, et al. Alleles at the dopamine D4 receptor locus do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am J Med Genet 1993; 48: 218-22.
50. Hong CJ, Chiu HJ, Chang YS, Sim CB. Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. Biol Psychiatry 1998; 43: 432-5.
51. Hong CJ, Lee YL, Sim CB, Hwu HG. Dopamine D4 receptor variants in Chinese sporadic and familial schizophrenics. Am J Med Genet 1997; 74: 412-5.
52. Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I, et al. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997; 7: 39-43.
53. Nanko S, Hattori M, Ikeda K, Sasaki T, Kazamatsuri H, Kuwata S. Dopamine D4 receptor polymorphism and schizophrenia. Lancet 1993; 341: 689-90.
54. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999; 258: 292-5.
55. Petronis A, Macciardi F, Athanassiades A, Paterson AD, Verga M, Meltzer HY, et al. Association study between the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1995; 60: 452-5.
56. Shaikh S, Gill M, Owen M, Asherson P, McGuffin P, Nanko S, et al. Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1994; 54: 8-11.
57. Sommer SS, Lind TJ, Heston LL, Sobell JL. Dopamine D4 receptor variants in unrelated schizophrenic cases and controls. Am J Med Genet 1993; 48: 90-3.
58. Tanaka T, Igarashi S, Onodera O, Tanaka H, Kameda K, Takahashi K, et al. Lack of association between dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1995; 60: 580-2.
59. Tani M, Koide S, Onishi H, Nakamura Y, Yamagami S. Association analysis of the SmaI polymorphism of the dopamine D4 receptor in Japanese schizophrenics. Psychiatr Genet 1997; 7: 137-9.
60. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-52.
61. Cohen BM, Ennulat DJ, Centorrino F, Matthysse S, Konieczna H, Chu HM, et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 1999; 141: 6-10.
62. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005; 115: 1539-47.
63. Kaiser R, Konneker M, Henneken M, Dettling M, Muller-Oerlinghausen B, Roots I, et al. Dopamine D4 receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000; 5: 418-24.
64. Rietschel M, Naber D, Oberlander H, Holzbach R, Fimmers R, Eggermann K, et al. Efficacy and side-effects of clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996; 15: 491-6.
65. Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D, et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003; 13: 183-5.
66. Zhou QY, Li C, Civelli O. Characterization of gene organization and promoter region of the rat dopamine D1 receptor gene. J Neurochem 1992; 59: 1875-83.
67. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003; 8: 109-13.
68. Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007; 21: 718-27.
69. Sherrington R, Mankoo B, Attwood J, Kalsi G, Curtis D, Buetow K, et al. Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics 1993; 18: 423-5.
70. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 2000; 403: 274-80.
71. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994; 63: 972-9.
72. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991-6.
73. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Mannisto PT. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 2002; 303: 1309-16.
74. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004; 24: 5331-5.
75. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol Psychiatry 2005; 57: 139-44.
76. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry 2005; 10: 765-70.
77. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006; 11: 867-77, 797.
78. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930-3.
79. Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: Influence on risk of schizophrenia. Hum Genet 2007; 120: 889-906.
80. Stefanis NC, Van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Hantoumi I, et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: A population study in 543 young men. Biol Psychiatry 2004; 56: 510-5.
81. Molero P, Ortuno F, Zalacain M, Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenom J 2007; 7: 418-26.
82. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798-805.
83. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. COMT gene polymorphism is associated with declarative memory in adulthood and old age. Behav Genet 2004; 34: 533-9.
84. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-22.
85. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: Differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004; 161: 359-61.
86. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677-82.
87. Kawarai T, Kawakami H, Yamamura Y, Nakamura S. Structure and organization of the gene encoding human dopamine transporter. Gene 1997; 195: 11-8.
88. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 2001; 432: 119-36.
89. Sesack SR, Hawrylak VA, Guido MA, Levey AI. Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 1998; 42: 171-4.
90. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104-6.
91. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114: 975-9.
92. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133-9.
93. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005; 46: 745-51.
94. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 2005; 6: 55.
95. Joober R, Toulouse A, Benkelfat C, Lal S, Bloom D, Labelle A, et al. DRD3 and DAT1 genes in schizophrenia: An association study. J Psychiatr Res 2000; 34: 285-91.
96. Kim JY, Jung IK, Han C, Cho SH, Kim L, Kim SH, et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci 2005; 59: 183-8.
97. Liddle PF, Lane CJ, Ngan ET. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 2000; 177: 402-7.
98. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmayer JP, et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 1998; 155: 337-43.
99. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr Res 2003; 60: 1-7.
100. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl) 2005; 178: 17-26.
101. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 2004; 29: 171-8.
102. Molina V, Gispert JD, Reig S, Pascau J, Martinez R, Sanz J, et al. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. Int Clin Psychopharmacol 2005; 20: 13-8
103. Buchsbaum MS, Haznedar MM, Aronowitz J, Brickman AM, Newmark RE, Bloom R, et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res 2007; 94: 293-305.
104. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999; 96: 13432-7
105. Schlagenhauf F, Wustenberg T, Schmack K, Dinges M, Wrase J, Koslowski M, et al. Switching schizophrenia patients from typical neuroleptics to olanzapine: Effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol 2008; 18: 589-99.
106. Braus DF, Ende G, Weber-Fahr W, Sartorius A, Krier A, Hubrich-Ungureanu P, et al. Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophr Res 1999; 39: 19-29.
107. Mattay VS, Callicott JH, Bertolino A, Santha AK, Tallent KA, Goldberg TE, et al. Abnormal functional lateralization of the sensorimotor cortex in patients with schizophrenia. Neuroreport 1997; 8: 2977-84.
108. Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O'Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med 2001; 31: 1065-78.
109. Bertolino A, Blasi G, Caforio G, Latorre V, De Candia M, Rubino V, et al. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: Effects of treatment with olanzapine. Biol Psychiatry 2004; 56: 190-7.
110. Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, et al. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: A functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci 2006; 256: 522-31.
111. Blasi G, Popolizio T, Taurisano P, Caforio G, Romano R, Di Giorgio A, et al. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry Res Neuroimaging. in press.
112. Fahim C, Stip E, Mancini-Marie A, Mensour B, Boulay LJ, Leroux JM, et al. Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: An fMRI study. Psychiatry Res 2005; 140: 1-15.
113. Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A, et al. Restoration of frontal activation during a treatment with quetiapine: An fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 21-6.
114. Simon J. The effects of an irrelevant directional cue on human information processing. In: Proctor R, Reeve T, Eds, Stimulus-Response Compatibility: An Integrated Perspective Amsterdam: North-Holland 1990; pp. 31-86.
115. Fusar-Poli P, Broome MR, Matthiasson P, Williams SC, Brammer M, McGuire PK. Effects of acute antipsychotic treatment on brain activation in first episode psychosis: An fMRI study. Eur Neuropsychopharmacol 2007; 17: 492-500.
116. Cardno AG, Gottesman, II. Twin studies of schizophrenia: From bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000; 97: 12-7.
117. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006; 14: 669-80.
118. Tsuang MT, Lyons MJ, Faraone SV. Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry 1990; 156: 17-26.
119. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45
120. Almasy L, Blangero J. Endophenotypes as quantitative risk factors for psychiatric disease: Rationale and study design. Am J Med Genet 2001; 105: 42-4.
121. Flint J, Munafo MR. The endophenotype concept in psychiatric genetics. Psychol Med 2007; 37: 163-80.
122. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7: 818-27
123. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996; 153: 1554-63.
124. Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A, et al. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry 2003; 160: 483-9.
125. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825-44.
126. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001; 11: 520-8.
127. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-71.
128. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572-5.
129. Squire LR. Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992; 99: 195-231.
130. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-13.
131. Breakspear M, Terry JR, Friston KJ. Modulation of excitatory synaptic coupling facilitates synchronization and complex dynamics in a biophysical model of neuronal dynamics. Network 2003; 14: 703-32.
132. Li SJ, Biswal B, Li Z, Risinger R, Rainey C, Cho JK, et al. Cocaine administration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI. Magn Reson Med 2000; 43: 45-51.
133. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74: 1-58.
134. Williams GV, Castner SA. Under the curve: Critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006; 139: 263-76.
135. Floresco SB, Grace AA. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J Neurosci 2003; 23: 3930-43.
136. Wang J, O'Donnell P. D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 2001; 11: 452-62.
137. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994; 6: 348-57.
138. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-6.
139. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-19.
140. Cichon S, Nothen MM, Stober G, Schroers R, Albus M, Maier W, et al. Systematic screening for mutations in the 5'-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder. Am J Med Genet 1996; 67: 424-8.
141. Rybakowski JK, Borkowska A, Czerski PM, Kapelski P, Dmitrzak-Weglarz M, Hauser J. An association study of dopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J Neural Transm 2005; 112: 1575-82.
142. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 809-15.
143. Bertolino A, Fazio L, Di Giorgio A, Blasi G, Romano R, Taurisano P, et al. Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. J Neurosci 2009; 29(4): 1224-34.
144. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, et al. DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science 1998; 281: 838-42.
145. Yoshimi A, Takahashi N, Saito S, Ito Y, Aleksic B, Usui H, et al. Genetic analysis of the gene coding for DARPP-32 (PPP1R1B) in Japanese patients with schizophrenia or bipolar disorder. Schizophr Res 2008; 100: 334-41.
146. Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007; 117: 672-82.
147. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
148. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 2008; 11: 197-205.
149. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118: 2200-8.
150. Bertolino A, Blasi G, Latorre V, Rubino V, Rampino A, Sinibaldi L, et al. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci 2006; 26: 3918-22.
151. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-91.
152. Sambataro F, Reed JD, Murty VP, Das S, Tan HY, Callicott JH, et al. Catechol-O-methyltransferase Val158Met polymorphism modulates brain networks underlying working memory across adulthood. Biolog Psychiatry (submitted).
153. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci USA 2007; 104: 12536-41.
154. Bertolino A, Di Giorgio A, Blasi G, Sambataro F, Caforio G, Sinibaldi L, et al. Epistasis between dopamine regulating genes identifies a nonlinear response of the human hippocampus during memory tasks. Biol Psychiatry 2008; 64: 226-34.
155. Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L, et al. Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry 2006; 60: 1250-8.
156. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-302.
157. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Callicott JH, Mattay VS, et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 2009; 45(1): 44-51.
158. Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, Bernstein HG, et al. The dopaminergic midbrain participates in human episodic memory formation: Evidence from genetic imaging. J Neurosci 2006; 26: 1407-17.
159. Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 2008; 17: 747-58.
160. Bertolino A, Caforio G, Blasi G, Rampino A, Nardini M, Weinberger DR, et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007; 95: 253-5.
161. Guo Y, DuBois Bowman F, Kilts C. Predicting the brain response to treatment using a Bayesian hierarchical model with application to a study of schizophrenia. Hum Brain Mapp 2008; 29: 1092-109.
162. Meyer-Lindenberg A, Nicodemus KK, Egan MF, Callicott JH, Mattay V, Weinberger DR. False positives in imaging genetics. Neuroimage 2008; 40: 655-61.
163. Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, Nguyen DD, et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull 2009; 35: 96-108.
164. Bansal AT, Barnes MR. Genomics in drug discovery: The best things come to those who wait. Curr Opin Drug Discov Devel 2008 May; 11(3): 303-11.
165. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.
166. Wurfel MM. Genetic insights into sepsis: What have we learned and how will it help? Curr Pharm Des 2008; 14(19): 1900-11.